Company: APXIF
Filing Date: 2025-06-13
Form Type: F-4/A
Source: 0001213900-25-054324
Chunk: 424

Company: APx Acquisition Corp. I
Filing Date: 2025-06-13
Form: F-4/A
Chunk 424
---
 $1,306,705 for the year ended June 30, 2023, to $1,885,895 for the year ended June 30, 2024. This increase was primarily due to changes in working capital, which included a $571,592 increase in inventories. This inventory buildup was strategically undertaken to meet expected demand and to mitigate potential supply chain risks and the possible adverse effects of economic policy changes during the period. To enhance liquidity, the Company also discounted deferred checks through financial institutions, primarily received from related parties for the sale of Heritas Diagnostics services. The Company continues to recognize the receivables and the amount received from the financial institution is recorded as a financial liability, and the cash received is classified as a financing cash inflow. When the cash is collected by the financial institution, the liability and the receivables are de -recognised. This transaction is reflected in the cash flow statement as an operating cash inflow for the reduction of the accounts receivable, and a financial cash outflow for the cancellation of the financial debt. Net cash generated from / (used in) investing activities Net cash generated from/(used in) investing activities changed by $26,216, from a net cash generated of $25,705 for the six months ended December31, 2023, to a net cash outflow of $511 for the six months ended December31, 2024. This change was primarily attributable to the absence of proceeds from disposals of short -terminvestments during the current period, compared to the $45,303 generated in the same period of 2023. Although capital expenditures decreased significantly, from $19,598 to $511, the lack of investment disposals resulted in a net outflow for the current period. Net cash used in investing activities changed by $529,988, from a net cash outflow of $529,825 for the year ended June 30, 2023, to a net cash inflow of $163 for the year ended June 30, 2024. This change was primarily attributable to the absence of capitalized expenditures on intangible assets, in comparison to the prior year, which included capital investments related to the development of new diagnostic tests for the Heritas Diagnostics segment and the Rewell platform.

219 It is important to note that, while the Company continued its research and development efforts related to the Rewell platform and the advancement of clinical genetic products during the year ended June 30, 2024 and through the six -